Want to see BIOQ full AI Analyst Report?
BIOQ Stock Chart & Stats
$33.75
$0.00(0.00%)
At close: 4:00 PM EDT
$33.75
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$32.50 - $45.00
Previous CloseN/A
Volume1.27K
Average Volume (3M)223.00
Market Cap
$30.17M
Enterprise Value$53.17
Total Cash (Recent Filing)$13.29M
Total Debt (Recent Filing)$33.48M
Price to Earnings (P/E)―
Beta-0.18
Next Earnings
Sep 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.38
Shares Outstanding893,838
10 Day Avg. Volume0
30 Day Avg. Volume223
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)1.11
Price to Sales (P/S)0.82
P/FCF Ratio14.87
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized NHP-focused CRO ServicesBioqual's niche expertise in non-human primate models creates high technical and regulatory barriers to entry, supporting durable demand from vaccine and therapeutic developers. This specialization fosters long-term client stickiness and pricing power for complex preclinical studies.
Stable Government & Institutional Client BaseLong-term contracts and relationships with government agencies and major pharma reduce revenue volatility and support predictable pipeline work. Institutional clients often fund multi-year programs, providing recurring revenue streams and credibility that underpin sustained demand.
Improved Cash GenerationThe shift to positive operating and free cash flow signals better internal funding capacity for operations and reinvestment without immediate reliance on equity financing. If sustained, this enhances financial flexibility and supports working capital for contract execution.
Bears Say
Declining Revenue And MarginsThree years of shrinking revenue and a recent negative gross profit indicate structural demand or pricing challenges and weak cost absorption. Persistent top-line decline undermines margin recovery and long-term profitability unless new contracts or higher-margin work materialize.
Rising LeverageA material increase in leverage reduces capital flexibility and increases fixed obligations. With profitability weak, higher debt intensifies refinancing and interest risks, limiting the firm's ability to invest in facility upgrades or scale without improving cash profits.
Operating Cash Flow Lags ObligationsAlthough cash flow turned positive, the decline versus prior year and weaker coverage of obligations suggests cash generation may be fragile. Sustained recovery requires consistent contract wins and margin improvement to cover debt service and capital needs.
Bioqual News
BIOQ FAQ
What was Bioqual Inc’s price range in the past 12 months?
Bioqual Inc lowest stock price was $32.50 and its highest was $45.00 in the past 12 months.
What is Bioqual Inc’s market cap?
Bioqual Inc’s market cap is $30.17M.
When is Bioqual Inc’s upcoming earnings report date?
Bioqual Inc’s upcoming earnings report date is Sep 18, 2026 which is in 50 days.
How were Bioqual Inc’s earnings last quarter?
Bioqual Inc released its earnings results on Apr 21, 2026. The company reported -$0.841 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Bioqual Inc overvalued?
According to Wall Street analysts Bioqual Inc’s price is currently Overvalued.
Does Bioqual Inc pay dividends?
Bioqual Inc pays a Annually dividend of $0.5 which represents an annual dividend yield of N/A. See more information on Bioqual Inc dividends here
What is Bioqual Inc’s EPS estimate?
Bioqual Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Bioqual Inc have?
Bioqual Inc has 893,838 shares outstanding.
What happened to Bioqual Inc’s price movement after its last earnings report?
Bioqual Inc reported an EPS of -$0.841 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Bioqual Inc?
Currently, no hedge funds are holding shares in BIOQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Bioqual Inc
Bioqual, Inc. delivers a range of preclinical research solutions, encompassing both in-vivo and in-vitro methodologies, to its diverse clientele of commercial enterprises and government agencies across the United States. Their expertise spans numerous critical health domains, including investigations into COVID-19, AIDS, influenza, RSV infection, and various flaviviruses such as Zika and Dengue. Furthermore, their work extends to malaria, hepatitis, and oncology. The firm's comprehensive laboratory capabilities further include processing biological samples, producing virus stocks, precisely quantifying infectious viral loads, and conducting assays like virus neutralization and hemagglutination inhibition. They also utilize advanced techniques such as quantitative PCR, ELISA for antigen and antibody detection, flow cytometry, lymphocyte proliferation studies, and various other cell-based analytical methods. Moreover, Bioqual furnishes specialized support for studies employing animal research models. Established in 1981, Bioqual, Inc. maintains its primary operational base in Rockville, Maryland.
Technical Analysis
Ownership Overview
―
Insiders
―
Mutual Funds
0.29% Other Institutional Investors
99.71% Public Companies and
Individual Investors